The company generates income by leasing out residential real estate and managing a portfolio of equity and mutual fund investments.
The company lacks a competitive advantage, as its primary income stems from a single residential property and passive investment holdings, with no proprietary scale or brand power. Financial returns are consistently poor, with negative net margins and returns on equity that fail to cover the cost of capital.
Capital is largely stagnant in passive investments and a single real estate asset. The company has failed to generate positive operating cash flow or meaningful business growth, and it does not pay dividends despite high theoretical intrinsic value.
Five years later, the investment has collapsed because the company remained a stagnant shell, eventually delisted by the exchange for persistent compliance failures. The theoretical intrinsic value proved to be a mirage as the single real estate asset deteriorated and the passive investment portfolio was drained by administrative costs and related-party transactions. Without an operating business to generate cash, the company was forced to liquidate assets at fire-sale prices to cover mounting regulatory fines and overhead, leaving minority shareholders with nothing but a lesson in the dangers of buying 'cheap' assets controlled by indifferent management.
RichFakir rates Satyam Silk Mills Ltd's business quality as poor — 21/100 on our quality score (profitability, growth, balance-sheet strength and capital allocation). We assess its competitive moat as none.
On our model, Satyam Silk Mills Ltd is trading about 66% below our estimate of fair value; we rate its price cheap. This is an educational estimate from public filings, not a recommendation.
RichFakir's educational verdict on Satyam Silk Mills Ltd is: Avoid. We are steering clear of this one — the red flags below outweigh anything the price or numbers offer.
RichFakir's educational estimate of Satyam Silk Mills Ltd's fair value is about ₹26 per share, derived from public filings. It's our estimate for research — not a price target or a recommendation to buy or sell.
View the full live analysis →